retatrutide mechanism of action triple agonist glp-1 gip glucagon Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing How Does Retatrutide Work? Doctor

Arguments for Game Changer Status Several compelling arguments support the characterization of GLP-1 agonists as transformative therapies: Unprecedented Efficacy : Tirzepatide marks a new era in overweight/obesity treatment, enabling many to achieve 20% weight loss [76] [77]

2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

They were even named 2023s breakthrough of the year by Science magazine

Clin Obes 13(5):e12593 Gloy VL et al (2013) Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials

Human islet isolation and culture Human islet studies were approved by the National Research Ethics Committee London (REC 07/H0711/114)